Potential of Favipiravir and Minocycline Combination Therapy for COVID-19

Since the outbreak and spread of COVID-19 in Japan, we have been investigating and anticipating the possibility of anti-inflammatory effects in combination therapy with antibacterial and antiviral agents. Minocycline is an antibacterial agent that has been validated for its anti-inflammatory effects...

Full description

Saved in:
Bibliographic Details
Published in:Re:GEN open 2022-01, Vol.2 (1), p.1-3
Main Authors: Itoh, Kazuhiro, Tsutani, Hiroshi, Iwasaki, Hiromichi
Format: Article
Language:English
Subjects:
COVID-19
favipiravir
inflammatory cytokine
Letter to the Editor
minocycline
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the outbreak and spread of COVID-19 in Japan, we have been investigating and anticipating the possibility of anti-inflammatory effects in combination therapy with antibacterial and antiviral agents. Minocycline is an antibacterial agent that has been validated for its anti-inflammatory effects and has a broad antibacterial spectrum. In the present study, we hypothesized the possibility of combination therapy with minocycline and favipiravir for COVID-19. Here, we validated our hypothesis based on the results of preliminary basic experiments and clinical trials. Large-scale clinical trials of minocycline and favipiravir combination therapy are warranted.
ISSN:2766-2705
2766-2705
DOI:10.1089/regen.2021.0037